Skip to Content

Emtricitabine Disease Interactions

There are 3 disease interactions with emtricitabine:

Major

Emtricitabine/tenofovir (applies to emtricitabine) hepatitis B

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Hepatitis

Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF) and may occur with discontinuation of other products containing these agents. It is recommended that patients with HIV-1 be tested for the presence of chronic hepatitis B virus (HBV) infection before or when initiating antiretroviral therapy. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue FTC and or TDF, or other products containing these drugs. If appropriate, anti-hepatitis B therapy may be warranted according to clinical practices, especially in patients with advanced liver disease or cirrhosis, since post-treatment exacerbation of hepatitis may lead to hepatic decompensation and liver failure.

Moderate

Emtricitabine (applies to emtricitabine) hemodialysis

Moderate Potential Hazard, High plausibility.

Emtricitabine is removed by hemodialysis. Following an emtricitabine dose administered 1.5 hours before the hemodialysis session, approximately 30% of the dose was removed over three hours of hemodialysis (blood flow rate of 400 mL/min and a dialysate flow rate of 600 mL/min). Emtricitabine should be administered after hemodialysis.

References

  1. "Product Information. Emtriva (emtricitabine)." Gilead Sciences, Foster City, CA.
Moderate

Emtricitabine (applies to emtricitabine) renal dysfunction

Moderate Potential Hazard, High plausibility.

Emtricitabine is primarily eliminated by the kidney. Compared to patients with normal renal function (CrCl above 80 mL/min), peak plasma concentration (Cmax) and systemic exposure (AUC) of emtricitabine increased by 45% and 113%, respectively, in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min), and 27% and 186%, respectively, in patients with severe renal dysfunction (CrCl below 30 mL/min). Systemic exposure was increased even further in patients with end-stage renal disease managed on dialysis. These patients had an approximately 3.5-fold increase in emtricitabine AUC compared to patients with normal renal function. Renal clearance of emtricitabine decreased by 68% and 86%, respectively, in patients with moderate and severe renal dysfunction. Dosage adjustment of emtricitabine is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer's product labeling. Clinical response to treatment and renal function should be closely monitored.

References

  1. "Product Information. Emtriva (emtricitabine)." Gilead Sciences, Foster City, CA.

Emtricitabine drug interactions

There are 34 drug interactions with emtricitabine

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.